Has Howard Burris, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,174,081 in general payments to Howard Burris, MD across 2,117 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Howard Burris, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Howard Burris, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Howard Burris, MD

Medical Oncology · Nashville, TNNPI 1417992397

Payments from drug & device makers

$12,174,081in general payments, 2019–2025

Across 2,117 payments — averaging $5750.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$3.4M
Merck$1.7M
Genentech, Inc.$1.3M
Seagen Inc.$748K
Agios Pharmaceuticals, Inc.$699K
AstraZeneca$447K
plus $3.8M from 54 others

$31,027in research payments, 2019–2025

Across 18 payments — averaging $1723.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$8K
Pfizer$8K
Eli Lilly$7K
Novartis$5K
Servier Affaires Medicales$2K
Novartis Pharma AG$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	14	$3,449,776
Merck	125	$1,717,287
Genentech, Inc.	321	$1,267,714
Seagen Inc.	178	$747,545
Agios Pharmaceuticals, Inc.	120	$698,615
AstraZeneca	35	$446,827
Servier Bioinnovation	51	$409,893
Takeda Pharmaceuticals U.S.A., Inc.	37	$376,452
E.r. Squibb & Sons, L.L.C.	13	$352,250
Servier Pharmaceuticals LLC	34	$338,775
Modernatx, Inc.	80	$335,210
Novartis	23	$311,351
EMD Serono, Inc.	295	$303,906
Incyte Corporation	256	$222,590
Ares Trading SA	77	$181,422
Array Biopharma Inc	76	$168,648
Sanofi US Services Inc.	49	$137,036
Tesaro, Inc.	15	$99,161
Eli Lilly	8	$96,172
GSK	20	$88,524
Macrogenics, Inc.	11	$68,513
Roche Products Limited	23	$58,615
TG Therapeutics, Inc.	47	$53,868
Hoffmann-la Roche Limited	8	$45,563
Pfizer	47	$45,078
Bayer	14	$26,374
Bristol Myers Squibb	6	$25,196
Gilead	19	$17,382
Beigene, Ltd.	2	$16,999
Sanofi Pasteur Inc.	10	$15,168
Foundation Medicine, Inc.	5	$15,000
F. Hoffmann-la Roche AG	8	$13,176
Jazz Pharmaceuticals Inc.	9	$9,315
Boehringer Ingelheim International GmbH	15	$8,311
Boehringer Ingelheim Pharma GmbH & Co.kg	4	$2,435
Verastem, Inc.	3	$1,854
Astrazeneca UK Limited	2	$526
Beigene USA, Inc.	3	$265
Exelixis Inc.	3	$174
Genentech USA, Inc.	3	$136
Astellas Pharma US Inc	8	$126
Daiichi Sankyo Inc.	5	$121
Eisai Inc.	3	$65
Pharmacyclics LLC, An Abbvie Company	2	$47
Amgen	3	$47
Taiho Oncology, Inc.	2	$41
Mirati Therapeutics, Inc.	2	$39
Novocure Inc.	1	$39
Clovis Oncology, Inc.	1	$36
Sanofi	1	$33
Johnson & Johnson	2	$33
Lexicon Pharmaceuticals, Inc.	2	$32
Lilly USA, LLC	1	$32
Tempus AI, Inc	1	$30
Regeneron Healthcare Solutions, Inc.	1	$26
G1 Therapeutics, Inc.	1	$24
Deciphera Pharmaceuticals Inc.	1	$22
Iovance Biotherapeutics, Inc.	1	$22
Genmab U.S., Inc.	1	$21
Verity Pharmaceuticals Inc.	1	$21

How this compares

$12,174,081 in reported general payments places this provider in the 95th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$272,274

Medicare patients

132

Services billed

15,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Nashville

Melissa JohnsonNashville$46M
David SpigelNashville$29.7M
Ingrid MayerNashville$6.3M
Jennifer ChoeNashville$4.1M
Cathy EngNashville$3.8M
Jordan BerlinNashville$3.7M
Kristen CiomborNashville$3.2M
Vandana AbramsonNashville$3M
Leora HornNashville$2.6M
Robert RamirezNashville$2.1M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →